Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Inreda Diabetic, Goor, the Netherlands.
Diabetes Care. 2021 Mar;44(3):836-838. doi: 10.2337/dc20-2106. Epub 2021 Jan 4.
To demonstrate the performance and safety of a bihormonal (insulin and glucagon) artificial pancreas (AP) in adults with type 1 diabetes.
In this outpatient, randomized, crossover trial, 2-week fully closed loop glucose control (AP therapy) was compared with 2-week open loop control (patient's normal insulin pump therapy with a glucose sensor if they had one).
A total of 23 patients were included in the analysis. Time in range (70-180 mg/dL [3.9-10 mmol/L]) was significantly higher during closed loop (median 86.6% of time [interquartile range 84.9-88.5]) compared with open loop (53.9% [49.7-67.2]; < 0.0001).
Compared with insulin pump therapy, the bihormonal AP provided superior glucose control, without meal or exercise announcements, and was safe in adults with type 1 diabetes.
展示双激素（胰岛素和胰高血糖素）人工胰腺（AP）在 1 型糖尿病成人患者中的性能和安全性。
在这项门诊、随机、交叉试验中，将为期 2 周的完全闭环血糖控制（AP 治疗）与为期 2 周的开环控制（患者使用正常胰岛素泵治疗，如果有血糖传感器则使用）进行比较。
共有 23 名患者纳入分析。闭环时的时间在目标范围内（70-180mg/dL [3.9-10mmol/L]）明显高于开环时（中位数 86.6%[75.3-88.5]）（<0.0001）。
与胰岛素泵治疗相比，双激素 AP 提供了更好的血糖控制，无需告知进餐或运动时间，并且在 1 型糖尿病成人患者中是安全的。
